Thermo Fisher Scientific Prostein Recombinant Rabbit Monoclonal Antibody (ZR9), RAbMono

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

Ready-to-use 150-200 µL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

ZR9

Immunogen

Synthesized peptides to the N-terminus of human protein if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Prostein,uniProtId:Q96JT2-1,ncbiNodeId:9606,antigenRange:1,antigenLength:553,antigenImageFileName:Z2006RP_Prostein_Q96JT2-1_Rabbit.svg,antigenImageFileNamePDP:Z2006RP_Prostein_Q96JT2-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Purification

Protein A

Storage buffer

tris with NP-40, BSA

Contains

<0.1% sodium azide

Storage conditions

4° C

Shipping conditions

Wet ice

Product Specific Information

This product is diluted and in a ready-to-use formulation.

A recommended positive control tissue for this product is Prostate, however positive controls are not limited to this tissue type.

The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.

Human protein is a 553 aa protein identified by cDNA library subtraction and subsequent high-throughput microarray screening of prostate cancer. Protein has multiple transmembrane domains. Protein has been shown to be uniquely expressed in normal and cancerous prostatic tissues. By immunohistochemistry, protein is expressed in the vast majority of normal and malignant prostatic tissues, regardless of grade and metastatic status. No protein expression is detected in normal and malignant tissue samples representing the great majority of essential tissues and tumors. In particular, protein is expressed in most of poorly differentiated prostatic carcinoma, including small cell prostate carcinoma. Protein is more specific and sensitive for prostatic carcinomas than PSA and PSAP.

Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.

Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Target Information

Prostein is a novel prostate-specific protein expressed in normal and malignant prostate tissues. This protein appears to be a type IIIa plasma membrane protein with a cleavable signal peptide and 11 transmembrane-spanning regions. Prostein expression is androgen responsive since treatment of LNCaP cells with androgen up-regulates prostein message and protein expression levels. Thus, prostein is a prostate-specific marker whose detection and quantitation may be useful in diagnosing and monitoring prostate cancer.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.